Ha Kung Wong

Ha Kung Wong

Partner, New York

Ha Kung Wong practices general intellectual property law with an emphasis on complex patent and trade secret litigation in pharmaceuticals, biologics and chemistry. Cases Ha Kung has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives and other pharmaceuticals. Mr. Wong also has extensive experience with inter partes review (IPR), intellectual property counseling, pre-suit investigations, licensing and due diligence.

Mr. Wong is the recipient of the 2017 ILO Client Choice Individual Award for Intellectual Property in New York. He is currently the Chair of the Recruiting Committee, serves as faculty for NITA (the National Institute of Trial Advocacy) and Lawline, and has been named a "Furthered 40" by Lawline for his contributions. He is also an Advisory Board Member for The Center for Biosimilars. 

Ha Kung was named to The National Law Journal's 2017 inaugural list of Elite Boutique Trailblazers.

Case Highlight

Ha Kung successfully represented Alkermes (Patent Owner) with respect to two related IPRs. The technology at issue related to injection formulations for microspheres that cover products such as Risperdal Consta® (risperidone) to treat schizophrenia and bipolar disorder, Vivitrol® (naltrexone) to treat alcohol and opioid dependence, and Bydureon® (exenatide extended-release) to treat type 2 diabetes.  The PTAB denied institution of one petition, and after oral argument, Ha Kung obtained a favorable ruling on the other petition as the PTAB found that the Petitioner failed to demonstrate that the claims of the patent at issue were unpatentable.

What Others Say
  • “Ha Kung Wong of Fitzpatrick is one of the best patent lawyers I’ve worked with. Not only does he have a sharp legal mind, but he has a sound business sense. His advice is always practical, and he is very responsive. In addition, Ha Kung is a pleasure to work with. I recommend him highly.” (Best Lawyers 2017)
  • “Ha Kung approaches matters pragmatically; he takes into account the commercial realities that in-house counsel must factor into their decisions.”(Client Choice 2017)
  • “Always well-prepared, gave excellent service and anticipated our company’s needs.” (LMG Life Sciences 2017)
  • “He understands the commercial big picture; he recognizes the nuances that often end up being the key to resolving the issue at hand.”(Client Choice 2017)
  • “Ha Kung stands out for his ability to handle the most complex IP issues; he provides solid, well-thought-out, quality and clearly communicated legal advice.”(Client Choice 2017)
  • “Ha Kung clearly loves his work and he excels in client service; he is friendly, a great communicator and responsive to the client's needs. (Client Choice 2017)
  • [is someone who has] “an eye for detail” and “goes the extra mile” (Legal 500 2008)
Representative Matters
  • Allergan against Wilshire, Somerset and Aurobindo on patents relating to ophthalmic formulations of alcaftadine for once daily treatment of allergic conjunctivitis.
  • Alnylam against Silence Therapeutics on patents relating to RNAi technology.
  • AstraZeneca against Andrx, Genpharm, Dr. Reddy and Schwartz Pharma on patents relating to omeprazole and its formulations.
  • Bristol-Myers Squibb against The Regents of the University of Michigan and Repligen Corp. and ZymoGenetics on patents relating to synthetic fusion proteins for regulating the immune system.
  • UCB against Mylan, Dr. Reddy, Sandoz and Cobalt on patents relating to levetiracetam, a leading epilepsy medicine.
  • GlaxoSmithKline against Barr Pharmaceuticals on patents relating to dutasteride, a leading BPH drug.
  • UCB and Celltech against KV Pharmaceutical on patents relating to methylphenidate hydrochloride, an ADHD medicine.
Events / Publications
News & Press